

## Postponement of Curexa Pharmacy project

In May 2024, QleanAir announced a cleanroom agreement with Curexa Pharmacy, with an order value of USD 2 500 000, which was planned for completion during 2024. QleanAir has today received information from Curexa Pharmacy that they postpone the project. At this time, QleanAir do not know what this means in time or possible extent. QleanAir sees a risk that the project will not be completed in 2024 and is working on getting a clear picture of the situation and to understand the consequences.

### For more information, please contact

---

Sebastian Lindström, CEO

[sebastian.lindstrom@qleanair.com](mailto:sebastian.lindstrom@qleanair.com)

+46 703 08 94 51

Henrik Resmark, CFO

[henrik.resmark@qleanair.com](mailto:henrik.resmark@qleanair.com)

+46 702 60 09 17

### About QleanAir

---

QleanAir is a niche premium provider of clean indoor environment solutions. The company's business model is based on rental contracts for modular solutions with a full-service offer. QleanAir's solutions are developed using filter technology that traps, filters and recycles indoor air. The company's main markets are EMEA, APAC and the Americas. QleanAir's head office is located in Solna, Sweden, and the share is traded on Nasdaq First North Premier Growth Market, ticker QAIR. FNCA Sweden is Certified Advisor. For more information go to [qleanair.com](https://qleanair.com).

### Attachments

---

[Postponement of Curexa Pharmacy project](#)